Maricann Group Inc. Enters Into Letter of Intent
TORONTO, ONTARIO–(Marketwired – Aug. 16, 2017) – Maricann Group Inc. (CSE:MARI)(“Maricann” or the “Company”) and a national provider that services pharmacies across Canada (the “Counterparty”), have agreed to a primary collaborative partnership through a joint initiative to create a pharmacy services program that enables pharmacists to counsel and appropriately educate patients in relation to medicinal cannabis.
By establishment of this education program for pharmacists to counsel patients, the Counterparty will expand the patient awareness of treatment options with their affiliated health care professionals, primarily through pharmacists to provide expert information to patients.
The joint initiative will aim to position pharmacies to be the preferred access point for medicinal cannabis based on pharmacists’ critical role in working with physicians and patients in understanding the multi-synchronistic opportunities in multi-medication patients. Maricann and the Counterparty will work together to assist patients in achieving their desired therapeutic goals while always keeping their safety paramount.
The letter of intent will form the basis of a definitive agreement to be executed by both parties at a future date. Details of that agreement will be announced upon completion.
Maricann, which has federal licenses in Canada to cultivate, extract, formulate and distribute cannabis, is rapidly expanding its Canadian production, based in Norfolk County, ON, adding 20,000 kg of dry flower production to come online in early 2018, and an additional 35,000 kg of production to come online in late 2018.
For more information about Maricann please visit our website at www.maricann.ca.
About Maricann Group Inc.
Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Toronto, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada. and Dresden, Saxony, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a fully funded 217,000 sq. ft. (20,159 sq. m) build out, to support existing and future patient growth.
Original press release: http://www.marketwired.com/press-release/maricann-group-inc-enters-into-letter-of-intent-cnsx-mari-2230462.htm
